Focus: Rein Therapeutics is a public biotech company headquartered in Austin, TX, focused on perpetually active peptides across nephrology, respiratory, and oncology indications. With 5,000+ employees, it operates at mid-to-large biotech scale.
Profile data last refreshed 21h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Rein Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Rein Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Rein Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Rein Therapeutics publishes LTI-03 presentation; Phase 1b biomarker signals and Phase 2 RENEW now enrolling - TradingView
Rein Therapeutics publishes LTI-03 presentation; Phase 1b biomarker signals and Phase 2 RENEW now enrolling TradingView
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - Yahoo Finance
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis Yahoo Finance
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview - TradingView
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview TradingView
Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates TradingKey
Certain Stock Options of Rein Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026. - marketscreener.com
Certain Stock Options of Rein Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026. marketscreener.com
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo